ReviewFrontiers in cell and developmental biology2026
Acetylation modification in malignant progression and therapeutic resistance of gliomas.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gliomas are the most common and aggressive primary malignant tumors of the central nervous system, characterized by diffuse infiltration, rapid proliferation and dismal prognosis. Despite advances in multimodal treatments, including surgical resection, radiotherapy and targeted therapies, clinical outcomes remain unsatisfactory owing to the inevitable development of therapeutic resistance. Protein acetylation, a key post-translational modification dynamically regulated by lysine acetyltransferases and deacetylases, plays a central role in governing chromatin organization, transcriptional regulation, protein stability and signal transduction. Increasing evidence indicates that aberrant acetylation critically contributes to glioma malignant progression and treatment resistance by modulating essential cellular processes, including proliferation, apoptosis, invasion, metabolic reprogramming, DNA damage repair, immune evasion and cancer stemness. This review systematically summarizes recent advances in understanding the roles of both histone and non-histone acetylation in glioma biology, with particular emphasis on their involvement in resistance to chemotherapy and radiotherapy. Collectively, this review underscores acetylation as a pivotal epigenetic mechanism driving glioma aggressiveness and therapeutic resistance and provides mechanistic insights and a conceptual framework for the development of more effective and precise therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.